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Implication for health policy/practice/research/medical education:
Kidney injury is common in patients with coronavirus disease 2019 (COVID-19). Most of the cases are presumed to be due to tubular injury. 
However, cases of glomerulopathy, particularly collapsing glomerulopathy (CG), are being increasingly reported, predominantly in patients 
of African ancestry.  Although the exact pathogenesis of CG in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection is 
still unsettled, accumulating evidence suggests this manifestation of kidney injury may be related to high risk APOL1 genetic susceptibility 
superimposed by a second hit by SARS-CoV-2, either directly or indirectly.
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Angiotensin-converting enzyme 2 
Cytokine storm
Acute renal impairment
Kidney is one of the most common organs affected by coronavirus disease 2019 (COVID-19) after the 
respiratory and immune systems. Among the renal parenchymal components, the tubulointerstitial 
compartment is presumed to be the prime target of injury in COVID-19. The main mechanism of renal 
tubular damage by COVID-19 is considered to be indirect, i.e., cytokine-mediated injury. A proportion 
of infected individuals mount a strong inflammatory response to the virus by an exaggerated immune 
response of the body, namely cytokine storm. Sudden and massive release of cytokines may lead to 
serious systemic hyper-inflammation and renal tubular injury and inflammation resulting in acute renal 
failure. In addition, a number of cases of glomerulopathies, particularly collapsing glomerulopathy 
(CG) have been reported, predominantly in people of African ancestry, as a rare form of kidney 
involvement by SARS-CoV-2 that may originate from the background genetic susceptibility in this 
population complicated by the second hit of SARS-CoV-2 infection, either directly or indirectly. It is 
noteworthy that renal injury in COVID-19 could be severe in individuals of African origin due to the 
aforementioned genetic susceptibility, especially the presence of high-risk apolipoprotein L1 (APOL1) 
genotypes. Although the exact mechanism of kidney injury by SARS-CoV-2 is as yet unknown, 
multiple mechanisms are likely involved in renal damage caused by this virus. This review was aimed 
to summarize the salient points of pathogenesis of kidney injury, particularly glomerular injury in 
COVID-19 disease in the light of published data. A clear understanding of these is imperative for 
the proper management of these cases. For this review, a search was made of Google Scholar, Web of 
Science, Scopus, EBSCO and PubMed for finding English language articles related to COVID-19, 
kidney injury and glomerulopathy. From the information given in finally selected papers, the key 
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Introduction
Coronavirus disease 2019 (COVID-19) is an emerging 
human infectious disease caused by a novel β-coronavirus, 
named severe acute respiratory syndrome coronavirus 2 
(SARS-CoV-2). Although it was first detected in Wuhan, 
China, in December 2019, it soon spread throughout 
the world and since then, over 13 million people around 
the world have been affected by the pandemic (1). While 
majority of cases are mild and self-limited presenting 
with upper respiratory tract symptoms, serious infection 
can occur in some individuals which can lead to serious 
complications and even death. The predominant organ 
involvement in individuals with SARS-CoV-2 is lung, 
which presents as a diffuse alveolar injury and pulmonary 
failure in severe cases (2). The virus may involve many 
other organs in severe cases, either directly or indirectly 
via a systemic hyperinflammatory response. A number 
of studies also reported acute renal dysfunction and 
other urinary abnormalities in the setting of moderate 
to severe COVID-19 disease (3). The precise mechanism 
of renal involvement and injury by SARS-CoV-2 has 
not yet been fully elucidated; but more and more data 
is accumulating on this topic. The most probable 
mechanisms are renal tubular damage due to cytokine 
storm, the direct cytopathic effect of the virus on tubular 
epithelial cells, and the glomerulopathy caused by 
immune mechanisms or direct cytopathic effects of the 
virus (4). For virus infectivity, the interaction of SARS 
viruses and angiotensin-converting enzyme 2 (ACE2) 
has been suggested as the prime factor. While the most 
frequent involved organ system is the pulmonary system 
presumably due to high expression of ACE2 in this 
system, involvement of other organs and body systems is 
not uncommon (4). Activation of angiotensin II pathway 
is also another possible mechanism of renal damage in 
COVID-19, since angiotensin II receptors have been 
suggested as a potential pathway contributing to viral 
infectivity and COVID-19-associated renal injury (5). 
Previous investigations showed that ACE2 is a membrane-
bound peptidase, which acts as a protein ligand for SARS-
CoV-2 binding in cell body, thereby permitting viral 
entrance and destruction of target organs. In fact, ACE2 
is abundantly expressed in renal tissue, particularly in the 
proximal renal tubular cells. Notably, the tubular ACE2 
expression in normal renal tissues is approximately one 
hundred times greater than that of the lungs (6). Likewise, 
there is a genetic deletion/insertion (D/I) polymorphism 
in intron 16 for activity of ACE1 for ACE concentration in 
tissues and blood. Therefore, the ACE polymorphism and 
vulnerability to COVID-19 can clarify the serious forms 
of SARS-CoV-2 among African American population 
versus the Caucasian population. In fact, the D allele of 
















             
       
       
       
       
             
             
             
             
             
              
 
  
Records identified by search of 
databases (n=179) 
Records after removal of 
duplications (n=145) 
Screening of titles and abstracts 
(n=49) 
Full-text articles evaluated 
(n=19) 
Studies included in qualitative 
synthesis (n=14) 
Excluded based on titles 
or abstract (n=30) 
Full texts excluded (n=5) 
Figure 1. Flowchart showing the study strategy and methodology 
used to obtain data for this review.
In this review, we briefly describe the most recent studies 
on COVID-19–associated glomerulopathy in addition to 
overall mechanisms of renal impairment in this disease. 
Methods 
For this review, we searched the following international 
databases; Google Scholar, Web of Science, Scopus, 
EBSCO and PubMed for finding English language 
articles related to COVID-19 and kidney injury 
from 1st January 2020 till 30th September 2020. The 
keywords included COVID-19, acute kidney injury, 
glomerulopathy, collapsing glomerulopathy, severe acute 
respiratory syndrome coronavirus 2 (SARS-CoV-2), acute 
renal injury, angiotensin-converting enzyme 2, acute renal 
failure, cytokine storm, APOL1 genotype, and proteinuria/
hematuria. All original and review articles and case reports 
relevant to this topic directly or indirectly were retrieved 
and carefully studied. From the information given in 
these papers, the following aspects were drawn out and 
presented in this narrative review for continued medical 
education (CME) of nephrology and nephropathology 
community. Figure 1 depicts the study methodology and 
strategy used to obtain data for this review.
 
Acute kidney injury in SARS-CoV-2
During the past few months of SARS-CoV-2 pandemic, 
numerous studies have reported that acute kidney injury 
occurs with wide incidence rate varying from 0.1% 
to 29% of hospitalized individuals (6). These studies 
showed that renal damage is reasonably frequent in 
this disease and contributes to the increased morbidity 
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and mortality in affected patients (2). Renal damage is 
characterized clinically by the presence of proteinuria 
(~44%), hematuria (~27%), and elevated plasma urea 
and creatinine (2,6). A study from China showed that 
15.5% of COVID-19 patients had some evidence of renal 
involvement, while 3.2% of them developed acute renal 
injury during hospitalization (8). Both acute kidney injury 
and proteinuria are associated with increased mortality (9). 
While, acute tubular injury has been suggested as the most 
probable cause of renal disturbance; it does not explain 
proteinuria, which could be massive in some cases, and 
also hematuria (9). Studies have also shown that baseline 
chronic kidney disease (CKD) or pre-existing acute renal 
impairment is associated with increased mortality (4,9). 
Renal tropism of this virus was detected by viral RNA 
in various renal structures of individuals who died from 
SARS-CoV-2, inclusive of glomeruli (3). In a more recent 
meta-analysis of five relevant studies and 964 COVID-19 
positive patients, the cumula tive event rate of acute renal 
failure was 7.1% (95% confidence interval [CI]: 1.8%–
24.5%, P<0.001, I2 = 92.4) (10).
Acute renal impairment in COVID-19 seems to develop 
from the interplay of several factors (Figure 2). To cite 
an example, fluid imbalance can lead to pre-renal acute 
renal failure, since recent data showed that 11% of SARS-
CoV-2 positive individuals develop nausea, vomiting, or 
diarrhea as a manifestation of gastrointestinal disturbance 
in this illness (11). However, the main mechanism which 
explains renal damage by COVID-19 is cytokine-mediated 
tubulointerstitial injury. A group of infected individuals 
develop a strong inflammatory phase of the disease by an 
exaggerated response of the body, named cytokine storm, 
leading to significant lung and systemic inflammation, 
which may be fatal. Cytokines are small molecules, which 
normally act as inflammatory mediators in the fight of 
immune system against infections. However, the abrupt, 
massive release of cytokines and chemokines such as IL-6, 
IL-21, IL-8, IL-1β, TNF-α, CCL-2, -3, -5 may lead to 
serious systemic inflammation and multi-organ damage 
(12). In an attempt to kill and overcome SARS-CoV-2 
virus, the resultant inflammatory response can destruct 
normal tissue, including renal parenchyma, particularly 
the renal tubular epithelial cells (13). Additionally, there 
may be rapid viral replication, viral-mediated ACE2 down-
regulation, cellular injury and shedding, leading to marked 
endothelial and epithelial cell loss and increased vascular 
permeability. These events trigger the production and 
release of chemokines and pro-inflammatory cytokines, 
which cause direct renal injury via apoptosis of kidney 
tubular epithelial cells (13). Thus, altered kidney function 
is an initial indicator of a hyper-inflammatory state; 
hence, assessment of renal function should be performed 
in all patients with COVID-19 (14). Furthermore, 
low concentration of oxygen in the circulation, due 
to pneumonia, could be another possible mechanism 
in causing renal impairment in COVID-19 infection 
(13). Other implicated factors for renal injury include 
diarrhea, disseminated intravascular coagulation, systemic 
hypotension, cardiac insufficiency, and dehydration in 
seriously ill cases infected with SARS-CoV-2. These 
conditions, in particular, intensify renal impairment in 
elderly with pre-existing diseases such as cardiovascular 
disease, diabetes or malignancy (15). Moreover, the 
acute viral myocarditis and cardiomyopathy could lead 
to hypotension and kidney hypoperfusion, resulting 
in reduction of glomerular filtration rate (7). Likewise, 
skeletal muscle damage, which has been detected in 19.3% 
of SARS-CoV-2 cases, leads to rhabdomyolysis, which can 
result in toxic renal tubular injury. Furthermore, use of 
contrast agents also elevates the risk of tubular toxicity. 
Other etiological factors consist of use of non-steroidal 
anti-inflammatory drugs, some antibiotics or antiviral 
agents, high dose of vitamin C particularly in elderly 
individuals and patients with underlying kidney disease 
(12,15). Studies regarding the long-term prognosis of 
acute kidney injury in COVID-19 patients are scarce and 
in progress. In previous studies, acute renal impairment 
was an independent risk factor for increased mortality. In 
addition, de novo proteinuria and hematuria were also 
independent predictors of increased mortality (5,16).
COVID-19-associated collapsing glomerulopathy
A small number of individual case reports and small case 
series, mostly from USA or Europe, have been published 
on glomerular involvement in COVID-19 infection 
predominantly in African American people (1-4,16-
Figure 2. Schematic diagram showing interplay of first and second 
hits in causing kidney injury (Not shown are background chronic 
kidney disease or concurrent kidney disease associated with lesions 
of COVID-19 infection).
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23). The prevalent glomerulopathic lesion noted is that 
of collapsing glomerulopathy (CG). CG is an unusual 
form of FSGS, which has been previously described in 
individuals infected with human immunodeficiency 
virus type 1 (HIV-1) (17). The first case was reported 
by Kissling et al, in which a 63-year-old black male 
patient with COVID-19 infection developed oliguria and 
rapidly developing acute kidney injury (KDIGO stage 3) 
during hospitalization. The patient also had past medical 
history of high blood pressure that was under treatment. 
In the kidney biopsy, they detected morphologic lesion 
resembling CG. Immunofluorescence study was non-
contributory. Electron microscopy showed podocytic 
vacuoles containing abundant spherical particles indicative 
of viral inclusion bodies resembling SARS-CoV-2. They 
concluded that CG, could be a consequence of direct viral 
effect on podocytes, possibly connected to the spectrum 
of coronavirus-related kidney involvement. There was 
no evidence of hilar variant of FSGS, which might be 
secondary to long-standing hypertension (23). 
High-risk APOL1 genotype and COVID-19-associated 
collapsing glomerulopathy
More recently, Magoon et al (4), reported two African 
American cases who presented with AKI in the setting 
of COVID-19 infection. Kidney biopsy specimens 
showed CG along with the presence of acute tubular 
injury. Importantly, both cases were homozygous for 
Apolipoprotein L1 (APOL1) (4). Magoon et al could not 
detect viral particles in biopsy specimens in their patients. 
Therefore, a direct cytopathic damage was not envisaged 
to be the main mechanism of glomerular injury in these 
cases. It is possible that the COVID-19 infection acted 
as a second hit in genetically susceptible subjects due to 
APOL1, in the development of collapsing FSGS (4).
CG is a severe form of diffuse podocytopathy caused by 
various pathophysiological mechanisms including a 
number of viral infections like parvovirus B-19, HIV or 
cytomegalovirus, and some other agents like drugs, for 
example, interferon (IFN) or pamidronate. Su et al 
reported renal histopathologic findings in the first ever 
detailed pathologic analysis of 26 postmortem specimens 
of individuals who died of respiratory failure due to 
COVID-19 disease. They demonstrated diffuse renal 
proximal tubular damage with loss of brush borders, non-
isometric vacuolization of tubular epithelial cells and even 
frank necrosis. Occasional hemosiderin granules and 
pigment casts were also noted. There were prominent red 
blood cell aggregates in peritubular capillaries obstructing 
the capillary lumens. In their series, there was not 
prominent and specific immune complex deposition, 
which ruled out the immune-mediated injury as the 
principal mode of injury. There were no features of 
vasculitis or thrombosis. However, ultrastructural 
examination showed viral inclusions in cell cytoplasm, 
mostly in proximal renal tubular epithelial cells and less 
commonly in distal tubular cells. They also found viral 
inclusions in podocytes (18). Larsen et al described kidney 
biopsy and the clinical course of a female African American 
patient affected by COVID-19, who presented with 
constitutional syndrome in addition to proteinuria, 
hematuria and renal failure. Patient also had a past medical 
history of diabetes and hypertension. However, renal 
biopsy showed only morphologic aspects of collapsing 
FSGS without pathologic findings of diabetic kidney 
disease. Their case was homozygous for the G1 risk allele 
(rs73885319) of APOL1. This, therefore, represented an 
aggressive APOL1-related collapsing FSGS triggered by 
SARS-CoV-2–related cytokine storm (2). Yet, another 
case of collapsing FSGS in a 46-year-old West African 
man with SARS-CoV-2 infection was reported by Peleg et 
al (16). This case was also homozygous for G1 allele of 
APOL1 gene. Particularly, lung involvement was mild in 
this case, however acute renal failure was significant and 
mandate kidney replacement therapy. However, ISH (in-
situ hybridization) for SARS-CoV-2 performed on 
formalin-fixed paraffin embedded kidney tissue sections 
was negative for the receptor binding domain of the spike 
protein of the virus. In contrast, Lazareth et al reported a 
patient of a 29-year-old renal transplant patient with sub-
Saharan origin, who presented with acute renal injury and 
proteinuria following COVID-19 infection. Renal graft 
biopsy showed morphologic lesions of CG while 
genotyping for two risk alleles of APOL1 gene showed 
low-risk G0/G2 alleles of the kidney donor. In another 
case report, Malhotra et al presented a 64-year-old African 
American case with history of CKD stage 3 and controlled 
HIV who developed AKI with worsening azotemia after 
he was treated for ARDS in result of SARS-CoV 2 and got 
total vitamin C dose 84 g as a part of his regimen for 1 
week. His renal biopsy findings support the diagnosis of 
CG concomitant with oxalate nephropathy because of 
high dosage of vitamin C. The APOL-1 risk variants 
expressed heterozygous of wild type and G1 variants, 
which are regarded as low-risks for CG. These case reports 
suggested that CG might be promoted by COVID-19 
even in the presence of a low-risk APOL1 genotype (3, 
19). Previous studies have shown that the APOL1 risk 
alleles are related to an increased proportion of newly 
diagnosed CG. More recent investigations suggest that 
renal expression of the APOL1 G1 and G2 risk variants 
could interfere with normal podocyte function. Besides, 
in the augmented inflammatory settings, Toll-like receptor 
agonists, IFNs and lipopolysaccharide substances, provoke 
APOL1 expression and its up-regulation (3). Furthermore, 
other cytokines and tumor necrosis factor (TNF) can also 
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stimulate APOL1 expression which causes severe damage 
to podocytes (20,21). The direct cytopathogenic effect of 
other viruses, like parvovirus B19, has been previously 
reported. This virus could involve renal tubular epithelial 
cells and podocytes provoking CG (17). Regarding HIV, a 
direct renal parenchymal infection including both the 
tubular epithelial cells and podocytes have been 
documented in the condition known as HIV-associated 
nephropathy (HIVAN). However, such evidence is not 
consistently observed in patients with coronavirus 
glomerular infection (6). In a previous study, Yeung et al 
showed that the Middle East respiratory syndrome-related 
coronavirus (MERS-CoV) was detected in podocytes and 
also in kidney tubular epithelium and was a cause of 
induced apoptosis (22). More recently, in 2 living 
individuals of COVID-19 disease, Couturier et al, 
reported collapsing FSGS with tubulointerstitial 
inflammation and fibrosis. However, using sensitive 
reverse transcriptase polymerase chain reaction techniques, 
they failed to find the virus in kidney tissue, blood or 
urine. They concluded that the renal lesions in COVID-19 
are possibly not due to direct virus invasion of the renal 
tissue (17). Another case of CG was reported by Kissling 
et al in a COVID-19 positive 63-year-old black man who 
was developed AKI in the background of hypertension. 
Shortly after admission, the patient developed oliguria 
and rapidly progressive acute kidney injury. Kidney biopsy 
lesions of CG and ultra-structural study showed 
coronavirus-like particles in the cytoplasm of podocytes. 
Importantly, the patient was homozygous for APOL1 G1 
variant (23). Other case reports showed different 
glomerular pathologies other than CG, for example, a 
report of de novo ANCA-associated glomerulonephritis in 
a 46-year-old South Asian COVID-19 positive male or 
report of a 65-year old Chinese female who developed 
kidney dysfunction with macroscopic hematuria and 
proteinuria during SARS-CoV-2 infection. She received a 
renal biopsy, which showed 2+ IgA mesangial deposits. 
Additionally, ultra-structural study showed electron-dense 
immune-type deposits in the mesangial area, while, there 
was no evidence of viral particles in the glomeruli (24). 
Similarly, Sharma et al reported two COVID-19 positive 
African American patients who developed acute renal 
impairment and proteinuria. The renal biopsies 
demonstrated collapsing FSGS associated with acute 
tubular injury and importantly, the presence of endothelial 
tubuloreticular bodies; however, the virus was not detected 
by electron microscopy. Both of their cases had APOL1 
high-risk genotypes (25). The recent case report by Larsen 
et al showed the presence of tubuloreticular inclusions in 
their case report of collapsing FSGS related to COVID-19. 
However, other case studies did not detect the evidence of 
direct renal infection by COVID-19 RNA; nevertheless, 
there is a possibility that the viral load was below the level 
for detection by the currently available techniques. 
Therefore, it is possible that collapsing FSGS may not be 
entirely the result of direct cytopathic effect of coronavirus. 
The other possible mechanisms may include the cytokine 
storm–induced damage, since the released cytokines may 
provoke apoptosis of glomerular cells (6). Hence, the 
development of collapsing FSGS in SARS-CoV-2 
infection may be the consequence of immune system 
activation by chemokines and IFN more than the direct 
infection of glomerular cells (26). In another case report 
by Gaillard et al, a 79-year-old SARS-CoV-2 positive 
African male with renal failure was presented. Electron 
microscopy on renal biopsy showed diffuse foot process 
effacement and marked cytoplasmic vacuolization of 
podocytes. Interestingly, they could show viral particles. 
They also detected diffuse endothelial injury and swelling, 
in both glomerular and peritubular capillaries. The 
immune reaction to this virus may stimulate type 1 IFN 
response, which may account for the glomerular and 
endothelial damage (27). In a more recent case series of 10 
renal biopsies who had clinical evidence of acute renal 
impairment and proteinuria in the background of 
COVID-19, Sharma et al showed presence of various 
degrees of acute tubular necrosis, and one patient had also 
myoglobin casts. Two of the patients had morphologic 
features of thrombotic microangiopathy, and another 
patient had pauci-immune crescentic glomerulonephritis. 
One of the cases had features of collapsing FSGS. Patients 
had mean age of 65 years, while five of them were black, 
three were Hispanic, and two were white. While, 8 
individuals had significant acute renal impairment, all of 
them had proteinuria. Despite severe SARS-CoV-2 
infection, they could not show the virus in biopsy samples 
of all 10 patients either by immunohistochemical or 
ultrastructural study (28).
Nlandu et al reported the first case of CG in a 48-year-
old African man from Congo co-infected by COVID-19 
and malaria. The patient achieved partial remission of 
proteinuria and partial improvement in kidney function. 
They did not test for APOL1 genotype due to non-
availability of the test. They claimed that this was the first 
report of glomerulopathy in COVID-19 patients from 
Africa (29), they also did not look for direct viral infection 
in the kidney tissue. 
Deshmukh et al reported the first case of CG in a 
42-year-old Indian origin man with COVID-19 infection 
(30). They did find evidence of direct viral infection 
of podocytes on electron microscopy. However, they 
could not perform APOL1 genotyping as the patient 
was lost to follow-up. A summary of studies describing 
glomerulopathies in patients with COVID-19 infection is 
provided in Table 1. 
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Conclusion
According to the above data, we can hypothesize that CG 
is a fulminant form of kidney injury by SARS-CoV-2 that 
may originate from genetic susceptibility complicated by 
the second hit of SARS-CoV-2 infection, affecting either 
directly or indirectly. It is noteworthy that renal injury 
in COVID-19 could be severe in individuals of African 
origin due to their genetic susceptibility, in the form of 
high-risk APOL1 genotypes or in lower risk heterozygous 
APOL-1 variants in the presence of overwhelming 
immune response.
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